GLS, the first enzyme catalyzing glutamine to glutamate to enter the TCA cycle [124], was identified from a genome-wide CRISPR screening aimed at identifying candidate targets that can synergize with FLT3-targeted therapy in AML [34]. The gene discussed is GLS; the disease is acute myeloid leukemia.